Respiratory function at follow-up after neonatal surfactant replacement therapy

Area of Science:

• Neonatology
• Pediatric Pulmonology
• Respiratory Physiology

Background:

• Preterm infants often experience respiratory distress due to immature lungs.
• Surfactant replacement therapy is used to improve lung function in neonates.
• Long-term effects of prophylactic surfactant therapy on respiratory mechanics require further investigation.

Purpose of the Study:

• To assess the long-term respiratory function in preterm infants following prophylactic surfactant replacement therapy.
• To compare lung function parameters between infants who received surfactant and those who received placebo.

Main Methods:

• A multi-center randomized placebo-controlled trial was conducted.
• Respiratory function was assessed in 17 preterm infants at a median of 7 months post-neonatal period.
• Measurements included functional residual capacity (FRC), thoracic gas volume (TGV), and airways resistance (RAW), with specific airways conductance (SGAW) calculated.

Main Results:

• No significant differences in FRC or TGV were observed between the surfactant and placebo groups.
• Airways resistance (RAW) was significantly lower in the surfactant group compared to the placebo group (P < 0.05).
• Specific airways conductance (SGAW) was significantly higher in the surfactant group than in the placebo group (P < 0.05).

Conclusions:

• Prophylactic surfactant replacement therapy in preterm infants leads to improved lung function at follow-up.
• The therapy demonstrates a positive impact on specific airways conductance and a reduction in airways resistance.
• These findings support the long-term benefits of surfactant therapy for respiratory health in preterm infants.